Table 4.

The relationship between antiplatelet agent use and 5-year rate of ischemic stroke recurrence among patients with first-time hemorrhagic stroke (n = 6180).

Variables	Number	Number of IS event	Person-years	Incidence rate per 100 person-years	Crude HR (95% CI)	Adjusted HR (95% CI)
Age
20–44	405	12	1782.4	0.67	Ref	Ref
45–59	2319	149	9696.5	1.54	2.27 (1.26–4.09)	1.98 (1.10–3.57)
≥ 60	3456	260	12,180.0	2.13	3.10 (1.75–5.53)	2.49 (1.38–4.47)
Sex
Female	2415	156	9258.4	1.68	Ref	Ref
Male	3765	265	14,400.5	1.84	1.09 (0.90–1.33)	1.18 (0.96–1.45)
Length of stay, days
< 9	1502	129	6133.4	2.10	Ref	Ref
≥ 9	4678	292	17,525.5	1.67	0.79 (0.64–0.97)	0.87 (0.7–1.09)
ICU
No	4945	364	19,444.9	1.87	Ref	Ref
Yes	1235	57	4214.0	1.35	0.72 (0.54–0.95)	0.86 (0.76–0.97)
CCI
< 5	4002	265	16,027.4	1.65	Ref	Ref
≥ 5	2178	156	7631.4	2.04	1.21 (0.99–1.48)	0.93 (0.74–1.17)
Antiplatelet agents
No	4120	262	14,777.1	1.77	Ref	Ref
Yes	2060	159	8881.8	1.79	1.02 (0.84–1.24)	0.8 (0.7–1.05)
Diabetes mellitus
No	4161	261	16,263.2	1.60	Ref	Ref
Yes	2019	160	7395.7	2.16	1.34 (1.10–1.63)	1.21 (0.97–1.50)
Hypertension
No	523	13	1944.2	0.67	Ref	Ref
Yes	5657	408	21,714.7	1.88	2.79 (1.60–4.84)	2.24 (1.27–3.93)
Hyperlipidemia
No	4185	264	15,572.2	1.70	Ref	Ref
Yes	1995	157	8086.7	1.94	1.15 (0.95–1.40)	1.03 (0.84–1.27)
AF
No	5919	388	22,843.5	1.70	Ref	Ref
Yes	261	33	815.3	4.05	2.32 (1.63–3.31)	1.87 (1.30–2.71)
CVD
No	4455	263	17,368.4	1.51	Ref	Ref
Yes	1725	158	6290.5	2.51	1.64 (1.35–2.00)	1.42 (1.15–1.77)
CHF
No	3267	197	12,734.5	1.55	Ref	Ref
Yes	2913	224	10,924.4	2.05	1.32 (1.09–1.59)	1.01 (0.82–1.24)
The history of IS
No	5905	391	22,855.6	1.71	Ref	Ref
Yes	275	30	803.3	3.73	2.13 (1.47–3.09)	1.56 (1.06–2.30)

ICU, intensive care unit; CI, confidence interval; AF, atrial fibrillation; CHF, congestive heart failure; IS, ischemic stroke; HR, hazard ratio; CVD, cardiovascular disease.